MediWound’s NexoBrid and EscharEx to be Featured at International Society for Burn Injuries 2016
August 24 2016 - 7:00AM
MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical
company bringing innovative therapies to address unmet needs in
severe burn and wound management, today announced that the
Company’s NexoBrid® and EscharEx® will be featured in multiple oral
and poster presentations at the 18th Congress of the International
Society for Burn Injuries (ISBI) taking place August 29 - September
1, 2016 in Miami, Florida. The presentation abstracts will be
available online at www.isbi2016.com.
“We are delighted to once again have NexoBrid
featured so prominently at this year’s ISBI, one of the world’s
premier clinical meetings focused on the treatment and prevention
of burns. The ISBI brings together the entire team of clinical
professionals involved in caring for patients with severe burns in
normal and mass casualties conditions on national and international
levels,” stated Gal Cohen, President and Chief Executive Officer of
MediWound.
“The presentations at ISBI highlight not only
the success of NexoBrid in routine clinical use, but also in real
life emergency situations such as the 2015 Romanian nightclub fire
that resulted in a burn mass casualty incident, which is one of the
featured oral presentations at the Congress,” added Mr. Cohen.
“ISBI’s mission this year is to further elevate the
standards-of-care in emerging countries where there are high burn
incidence rates and more limited surgical capacity. We share their
goals and look forward to the opportunity to communicate with
leading burn specialists from Latin America, Asia-Pacific and other
international regions in order to expand NexoBrid access to
additional international markets where an effective non-surgical
eschar removal agent can further improve burn care management and
become the new standard-of-care for severe burns.”
The following abstracts regarding NexoBrid have
been accepted for presentation by the ISBI organizing
committee:
|
|
Paper
Title:
|
“A Medical Training Program for the Introduction of
NexoBrid Enzymatic Debridement to the Burn Community” |
Date/Time: |
August 29th from 12:30 p.m. – 1:30 p.m. |
Location: |
Exhibit Hall |
|
|
Paper
Title: |
“Low Exposure Levels of Respirable Particles during the
Preparation of NexoBrid® Bromelain Powder” |
Date/Time: |
August 29th from 12:30 p.m. – 1:30 p.m. |
Location: |
Exhibit Hall |
|
|
Paper
Title: |
“2015 Bucharest Night Club Fire” |
Date/Time: |
August 29th from 1:30 p.m. – 3:00 p.m. |
Location: |
Brickell |
|
|
Paper
Title: |
“Burn Depth Assessment: Laser Doppler Imaging (LDI) vs.
Enzymatic Debridement” |
Date/Time: |
August 29th from 3:30 p.m. – 5:00 p.m. |
Location: |
Flagler |
|
|
Paper
Title: |
“The Use of Rapid Enzymatic Debridement in the 2015
Romanian Burn Mass Casualty Incident: Groundbreaking
Experience” |
Date/Time: |
August 29th from 3:30 p.m. – 5:00 p.m. |
Location: |
Tuttle |
|
|
Paper
Title: |
“Rapid Enzymatic Debridement of Chronic Wounds: Results of
a Multicenter Phase II Trial” |
Date/Time: |
August 30th from 12:30 p.m. – 1:30 p.m. |
Location: |
Exhibit Hall |
|
|
Paper
Title: |
“Early Debridement of Sulfur Mustard Contaminated Skin by
NexoBrid: Results of a Concept Validation Pig Model
Study” |
Date/Time: |
August 30th from 3:30 p.m. – 5:00 p.m. |
Location: |
Jasmine |
|
|
Paper
Title: |
“New Experience with NexoBrid in Milan Burn Centre: Pros
and Cons” |
Date/Time: |
August 30th at 3:30 p.m. – 5:00 p.m. |
Location: |
Brickell |
|
|
Paper
Title: |
“Acute Healing and Early Scarring after Tissue Preserving
Enzymatic Debridement of 13 Severely Burned Faces Compared to
Traditional Surgical Debridement” |
Date/Time: |
August 30th from 3:30 p.m. – 5:00 p.m. |
Location: |
Monroe |
|
|
Paper
Title: |
“Introduction of NexoBrid for Wound Management: Lessons
Learned after the First 25 Patients (1 year)” |
Date/Time: |
August 30th from 3:30 p.m. – 5:00 p.m. |
Location: |
Monroe |
|
|
Paper
Title: |
“The Role of Rapid Enzymatic Escharotomy and Escharectomy
in Burn Mass Casualty Incidents” |
Date/Time: |
August 31st at 12:30 p.m. – 1:30 p.m. |
Location: |
Exhibit Hall |
|
|
Paper
Title: |
“Use of Enzymatic Debridement in Electrical Burn Injuries:
A Case Report” |
Date/Time: |
August 31st at 12:30 p.m. – 1:30 p.m. |
Location: |
Exhibit Hall |
|
|
Paper
Title: |
“In Vivo Analysis of NexoBrid Enzymatic Debridement of Full
Thickness Burns and Negative Pressure Wound Therapy” |
Date/Time: |
August 31st at 12:30 p.m. – 1:30 p.m. |
Location: |
Exhibit Hall |
|
|
Paper
Title: |
“The Treatment of Deep Partial Thickness Hand Burns after
Enzymatic Debridement with NexoBrid: A Series of Case
Reports” |
Date/Time: |
September 1st at 10:30 a.m. – 12:00 p.m. |
Location: |
Flagler |
|
|
About the ISBIThe International
Society for Burn Injuries (ISBI) had its beginnings at the First
International Congress on Research in Burns in Bethesda, Maryland
in September 1960. Since the ISBI was founded, the total medical
care of burn patients has improved considerably. This is not only
because medical science has improved but also because there is also
a better understanding of the need for a team of professionals of
different specialties such as surgeons, anesthetists,
bacteriologists, critical care physicians, nurses, dietitians,
physiotherapists and others. Each and every one of these
specialists plays a very important role. One of the main
purposes and aims of the ISBI is to disseminate knowledge and to
stimulate prevention in the field of burns.
About NexoBrid
NexoBrid is an easy-to-use, topically-applied
product that removes dead or damaged tissue, known as eschar, in
approximately four hours without harming the surrounding healthy
tissues. NexoBrid received marketing authorization from the
European Medicines Agency for the removal of eschar in adults with
deep partial and full-thickness thermal burns, is commercially
available in Europe, Israel and Argentina. Representing a new
paradigm in burn care management, NexoBrid demonstrated in clinical
studies, with statistical significance, its ability to
non-surgically and rapidly remove the eschar earlier than other
modalities, without harming viable tissues. The removal of eschar
or “debridement” is a critical first step in the successful healing
of severe burns and chronic and other hard-to-heal wounds. With the
current standard of care, burn eschar is removed either with
existing topical agents that have been found to be minimally
effective or that take a significantly longer period of time to
work, or by resorting to non-selective surgery, which is traumatic
and may result in loss of blood and viable tissue necessitating
further surgical treatments. The U.S. Phase 3 clinical trial and
registration process for NexoBrid is being funded in whole or in
part with federal funds under a contract with the Office of the
Assistant Secretary for Preparedness and Response, Biomedical
Advanced Research and Development Authority.
About MediWound Ltd.
MediWound is a fully-integrated
biopharmaceutical company focused on developing, manufacturing and
commercializing novel therapeutics based on its patented
proteolytic enzyme technology to address unmet needs in the fields
of severe burns, chronic and other hard-to-heal wounds. MediWound’s
first innovative biopharmaceutical product, NexoBrid®, received
marketing authorization from the European Medicines Agency as well
as the Israeli and Argentinian Ministries of Health, for removal of
dead or damaged tissue, known as eschar, in adults with deep
partial and full-thickness thermal burns and was launched in
Europe, Israel and Argentina. NexoBrid represents a new
paradigm in burn care management, and clinical trials have
demonstrated, with statistical significance, its ability to
non-surgically and rapidly remove the eschar earlier and without
harming viable tissue.
MediWound's second innovative product,
EscharEx®, is a topical biological drug being developed for
debridement of chronic and other hard-to-heal wounds and is
complementary to the large number of existing wound healing
products, which require a clean wound bed in order to heal the
wound. EscharEx contains the same proteolytic enzyme technology as
NexoBrid, and benefits from the wealth of existing development data
on NexoBrid. In two Phase 2 studies, EscharEx demonstrated
safety and efficacy in the debridement of chronic and other
hard-to-heal wounds, within a few daily applications.
For more information, please visit
www.mediwound.com.
Cautionary Note Regarding
Forward-Looking Statements
This release includes forward-looking statements
within the meaning of Section 27A of the U.S. Securities Act of
1933, as amended, Section 21E of the US Securities Exchange Act of
1934, as amended, and the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Forward-looking
statements are statements that are not historical facts, such as
statements regarding assumptions and results related to the
regulatory authorizations and launch dates. In some cases, you
can identify forward-looking statements by terminology such as
“believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,”
“should,” “plan,” “expect,” “predict,” “potential,” or the negative
of these terms or other similar expressions. Forward-looking
statements are based on MediWound’s current knowledge and its
present beliefs and expectations regarding possible future events
and are subject to risks, uncertainties and assumptions. Actual
results and the timing of events could differ materially from those
anticipated in these forward-looking statements as a result of
several factors. In particular, you should consider the risks
discussed under the heading “Risk Factors” in our annual report on
Form 20-F for the year ended December 31, 2015 and information
contained in other documents filed with or furnished to the
Securities and Exchange Commission. You should not rely upon
forward-looking statements as predictions of future events.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee that
future results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or will occur. The forward-looking statements made herein
speak only as of the date of this announcement and MediWound
undertakes no obligation to update publicly such forward-looking
statements to reflect subsequent events or circumstances, except as
otherwise required by law.
|
|
|
|
|
|
Contacts: |
|
|
|
|
Anne Marie Fields |
Sharon Malka |
|
|
|
|
Senior Vice President |
Chief Financial and Operations Officer |
|
|
|
|
LHA |
MediWound |
|
|
|
|
212-838-3777 |
ir@mediwound.co.il |
|
|
|
|
afields@lhai.com |
MediWound (NASDAQ:MDWD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MediWound (NASDAQ:MDWD)
Historical Stock Chart
From Apr 2023 to Apr 2024